Ferrosan's 2006 income grows 25%

Ferrosan, a Danish consumer and professional health care company, recorded solid growth in 2006. Revenue for the full year grew 24.9% on the like, year-ago period to 1.14 billion Danish kroner ($204.0 million), marking the first time the company has generated annual turnover of more than 1.0 billion kroner.

During the period, operating profit soared 67% to 156.6 million kroner as net profit reached 85.2 million kroner against 42.2 million kroner in 2005.

2006 was a good year for Ferrosan's core products, with overall organic growth of 8.9% versus 2% in 2005. Multi-tabs, the firm's vitamin and mineral supplement, performed well, improving its performance in all major markets. In particular, the important Russian market saw satisfactory developments due to increased focus on medical marketing and a stronger partnership with the retail sector. Sales of Idoform/Bifiform, the company's probiotic used to prevent and treat mild diarrhea, accelerated in Russia, Norway and the Ukraine. Ferrosan increased its share of these markets during the year and fortified its position by launching a product for children. Nordic Sales Group, which sells supplements to consumers by subscription, sustained solid growth, both within its core product Fri Flyt, omega-3 fish oil capsules, and other supplements.